B-cell chronic lymphocytic leukemia
Information
- Disease name
- B-cell chronic lymphocytic leukemia
- Disease ID
- Description
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT03088878 | Active, not recruiting | Phase 1/Phase 2 | A Study of Cirmtuzumab and Ibrutinib in Patients With B-Cell Lymphoid Malignancies | January 3, 2018 | August 30, 2024 |
| NCT05094206 | Active, not recruiting | Phase 1 | CAR20.19.22 T-cells in Relapsed, Refractory B-cell Malignancies | June 30, 2022 | February 2026 |
| NCT02213913 | Active, not recruiting | Phase 1/Phase 2 | Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphomas | July 29, 2014 | July 29, 2023 |
| NCT03204188 | Active, not recruiting | Phase 2 | Ibrutinib, Fludarabine, and Pembrolizumab in High-Risk or Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | September 22, 2017 | December 31, 2026 |
| NCT02437019 | Approved for marketing | Early Access Program (EAP) for Ibrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) | |||
| NCT00086580 | Completed | Phase 3 | Fludarabine (Fludara®) Plus Alemtuzumab (CAMPATH®, MabCampath®) vs Fludarabine Alone in B-Cell Chronic Lymphocytic Leukemia (B-CLL) Patients | July 2004 | June 2010 |
| NCT00098670 | Completed | Phase 2 | Fludarabine, Rituximab, and Alemtuzumab in Treating Patients With Chronic Lymphocytic Leukemia | October 2004 | February 2011 |
| NCT00119392 | Completed | Phase 2 | Yttrium Y 90 Ibritumomab Tiuxetan, Fludarabine, Radiation Therapy, and Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma | June 2004 | April 23, 2016 |
| NCT00147901 | Completed | Phase 2 | Fludarabine, Cyclophosphamide, and Alemtuzumab in Patients With B-cell Chronic Lymphatic Leukemia (B-CLL) | January 2005 | November 2011 |
| NCT00254163 | Completed | Phase 3 | Fludarabine, Cyclophosphamide, and Rituximab Versus Pentostatin, Cyclophosphamide, and Rituximab in Previously Untreated or Treated B-Cell Chronic Lymphocytic Leukemia Patients | December 2003 | September 2011 |
| NCT00290472 | Completed | Phase 2 | CCI-779 in Treating Patients With Recurrent or Refractory B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia | March 2004 | April 2010 |
| NCT00290810 | Completed | Phase 2 | Bevacizumab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia | December 2005 | August 2010 |
| NCT00321724 | Completed | Phase 2 | AZD2171 in Treating Patients With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia | May 2006 | |
| NCT00005799 | Completed | N/A | Fludarabine Phosphate, Low-Dose Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney Cancer | November 1999 | |
| NCT00006226 | Completed | Phase 2 | Thalidomide in Treating Patients With Relapsed Chronic Lymphocytic Leukemia | September 2000 | |
| NCT00058227 | Completed | Phase 1 | Alvocidib, Fludarabine Phosphate, and Rituximab in Treating Patients With Lymphoproliferative Disorders or Mantle Cell Lymphoma | April 2003 | |
| NCT00058240 | Completed | Phase 1/Phase 2 | Flavopiridol in Treating Patients With Previously Treated Chronic Lymphocytic Leukemia or Lymphocytic Lymphoma | April 2003 | February 2009 |
| NCT00003620 | Completed | Phase 2 | Flavopiridol in Treating Patients With Chronic Lymphocytic Leukemia | June 1999 | |
| NCT00398112 | Completed | Phase 2 | Sunitinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | August 2007 | January 2011 |
| NCT00435084 | Completed | Phase 1/Phase 2 | A Phase I/II Study to Assess the Safety and Tolerability of APO866 for the Treatment of Refractory B-CLL | February 2007 | April 2009 |
| NCT00565981 | Completed | Phase 2 | A Pilot Trial With Subcutaneous Alemtuzumab and Oral Fludarabinephosphate for the Determination of Safety, Efficacy and Molecular Profiling for the Prediction of Response | March 2004 | February 13, 2008 |
| NCT00621452 | Completed | Phase 1 | Genetically Engineered Lymphocytes, Cyclophosphamide, and Aldesleukin in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or Indolent B-Cell Non-Hodgkin Lymphoma | August 2007 | |
| NCT00697346 | Completed | Phase 1 | Study of MLN8237 in Participants With Advanced Hematological Malignancies | July 11, 2008 | October 19, 2016 |
| NCT00774345 | Completed | Phase 3 | A Study to Evaluate the Efficacy and Safety of Lenalidomide as Maintenance Therapy for Patients With B-Cell Chronic Lymphocytic Leukemia (CLL) Following Second Line Therapy | January 27, 2009 | October 27, 2020 |
| NCT00867529 | Completed | Phase 2 | Rituximab in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant for Relapsed or Refractory B-cell Lymphoma | February 2009 | March 26, 2015 |
| NCT00910910 | Completed | Phase 3 | Study Of The Effectiveness & Safety Of Lenalidomide Versus Chlorambucil As First Line Therapy For Elderly Patients With B-Cell CLL (The ORIGIN Trial) | October 13, 2009 | May 9, 2018 |
| NCT01029366 | Completed | Phase 1 | CART19 to Treat B-Cell Leukemia or Lymphoma That Are Resistant or Refractory to Chemotherapy | March 17, 2010 | May 2016 |
| NCT01105247 | Completed | Phase 1/Phase 2 | Safety of PCI-32765 in Chronic Lymphocytic Leukemia | May 2010 | February 2013 |
| NCT01109069 | Completed | Phase 2 | Safety and Tolerability Study of PCI-32765 in B Cell Lymphoma and Chronic Lymphocytic Leukemia | June 2010 | April 26, 2019 |
| NCT01110473 | Completed | Phase 1 | ABT-348 as Monotherapy and in Combination With Azacitidine to Treat Advanced Hematologic Malignancies | April 2010 | June 2013 |
| NCT01144260 | Completed | Phase 2 | Study of Bafetinib as Treatment for Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia (B-CLL) | June 2010 | April 2013 |
| NCT01212380 | Completed | Phase 1 | Study of Carfilzomib in Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL) or Prolymphocytic Leukemia (PLL) | October 2010 | September 2015 |
| NCT01217749 | Completed | Phase 1/Phase 2 | Efficacy and Safety Study of PCI-32765 Combine With Ofatumumab in CLL | December 2010 | May 2014 |
| NCT01258998 | Completed | Phase 2 | Study of Akt Inhibitor MK2206 in Patients With Relapsed Lymphoma | December 2010 | August 2015 |
| NCT01269385 | Completed | Phase 1/Phase 2 | Imprime PGG, Alemtuzumab, and Rituximab in Treating Patients With High Risk Chronic Lymphocytic Leukemia | January 2011 | June 2015 |
| NCT01292135 | Completed | Phase 1 | Safety and Tolerability Study of PCI-32765 Combined With Fludarabine/Cyclophosphamide/Rituximab (FCR) and Bendamustine/Rituximab (BR) in Chronic Lymphocytic Leukemia (CLL) | February 2011 | May 2013 |
| NCT01576588 | Completed | Phase 2 | Rituximab in Pretreated Elderly or Unfit B-CLL Patients | October 2011 | June 2019 |
| NCT01789255 | Completed | Phase 2 | Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hematological Malignancies | June 2013 | March 2014 |
| NCT02037256 | Completed | N/A | Bortezomib and Filgrastim to Promote Stem Cell Mobilization in Patients With Non-Hodgkin Lymphoma or Multiple Myeloma | July 2011 | January 21, 2015 |
| NCT02381080 | Completed | Phase 1 | Interaction Study of Ibrutinib and Cytochrome P450 (CYP) 3A Inhibitors in Participants With B-cell Malignancy | May 19, 2015 | June 24, 2016 |
| NCT03097770 | Completed | Phase 1/Phase 2 | Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD20 | April 1, 2017 | January 31, 2020 |
| NCT03755947 | Completed | Phase 2 | Ibrutinib, Obinutuzumab and Venetoclax for Patients With Chronic Lymphocytic Leukemia | December 1, 2018 | February 1, 2021 |
| NCT04030195 | Completed | Phase 1/Phase 2 | Dose-escalation Study of Safety of PBCAR20A in Subjects With r/r NHL or r/r CLL/SLL | March 24, 2020 | June 24, 2021 |
| NCT06364423 | Not yet recruiting | Phase 1/Phase 2 | Anti-CD19 Chimeric Antigen Receptor T-Cell Immunotherapy for Chronic Lymphocytic Leukemia (CLL) | June 23, 2024 | July 1, 2030 |
| NCT05797233 | Recruiting | Phase 1 | Trial of Anti-CD19 and Anti-CD20 Bicistronic Chimeric Antigen Receptor T Cells for Treating B-Cell Malignancies | August 28, 2023 | December 30, 2029 |
| NCT05645107 | Recruiting | Phase 3 | A Study to Evaluate Efficacy, Safety, and Pharmacokinetics of XEMBIFY® Plus Standard Medical Treatment (SMT) Compared to Placebo Plus SMT to Prevent Infections in Participants With Hypogammaglobulinemia and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia | December 26, 2022 | June 2026 |
| NCT01982175 | Suspended | Phase 2 | Phase II Clinical Trial of Alemtuzumab to Treat B-cell Chronic Lymphocytic Leukemia | July 2011 | June 2022 |
| NCT02440685 | Terminated | Phase 1/Phase 2 | A Phase 1/2 Study To Evaluate ASN002 In Relapsed/Refractory Lymphoma And Advanced Solid Tumors | May 2015 | July 2018 |
| NCT00098488 | Terminated | Phase 1 | 17-N-Allylamino-17-Demethoxygeldanamycin With or Without Rituximab in Treating Patients With Relapsed B-Cell Chronic Lymphocytic Leukemia or Prolymphocytic Leukemia | April 2005 | |
| NCT00098371 | Terminated | Phase 2 | Flavopiridol in Treating Patients With Chronic Lymphocytic Leukemia or Prolymphocytic Leukemia | April 2005 | November 2012 |
| NCT00344786 | Terminated | Phase 1 | Phase 1, Dose-Escalation Study of Oral CNF2024(BIIB021) in CLL | February 2006 | September 2008 |
| NCT00377104 | Terminated | Phase 1 | Alvocidib in Treating Patients With B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | September 2006 | |
| NCT00612612 | Terminated | Phase 1 | Obatoclax, Fludarabine, and Rituximab in Treating Patients With Previously Treated Chronic Lymphocytic Leukemia | January 2008 | |
| NCT04160195 | Terminated | Phase 1 | T Cells Expressing Fully-human Anti-CD19 and Anti-CD20 Chimeric Antigen Receptors for Treating B-cell Malignancies and Hodgkin Lymphoma | December 20, 2019 | June 11, 2021 |
| NCT00646165 | Terminated | Phase 1 | Trial of Forodesine in Patients With Relapsed B-cell Chronic Lymphocytic Leukemia | July 2008 | May 2009 |
| NCT00648739 | Terminated | Phase 1/Phase 2 | Safety and Dose Ranging Study of Samalizumab to Treat Relapsing or Refractory CLL or MM | June 19, 2008 | December 14, 2010 |
| NCT02168907 | Terminated | Phase 1 | CPI-613, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma | December 2014 | February 2015 |
| NCT00771056 | Terminated | Phase 2 | Hydroxychloroquine in Untreated B-CLL Patients | July 2008 | January 2012 |
| NCT00288067 | Terminated | Phase 1/Phase 2 | Fenretinide and Rituximab in Treating Patients With B-Cell Non-Hodgkin Lymphoma | October 2005 | July 2013 |
| NCT02336048 | Terminated | Phase 1 | A Study Evaluating the Safety of Tocilizumab in Addition to Standard of Care Premedication Given Before Obinutuzumab + Chlorambucil in Participants With Untreated B-Cell Chronic Lymphocytic Leukemia (B-CLL) and Comorbidities | June 26, 2015 | September 21, 2018 |
| NCT00089076 | Terminated | Phase 1/Phase 2 | MDX-010 in Treating Patients With Recurrent or Refractory Lymphoma | June 2004 | October 2009 |
| NCT00101205 | Terminated | Phase 1 | Oxaliplatin, Ifosfamide and Etoposide in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma | November 2004 | |
| NCT01126502 | Terminated | Phase 1 | Alvespimycin Hydrochloride in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-Cell Prolymphocytic Leukemia | May 2010 | June 2012 |
| NCT01604031 | Terminated | Phase 1 | Treatment of B-CLL With Autologous IL2 and CD40 Ligand-Expressing Tumor Cells + Lenalidomide | February 2013 | April 2015 |
| NCT01649791 | Terminated | N/A | Lenalidomide as Chemoprevention in Treating Patients With High-Risk, Early-Stage B-Cell Chronic Lymphocytic Leukemia | January 2010 | October 2014 |
| NCT00302861 | Terminated | Phase 1/Phase 2 | A Study to Evaluate the Treatment of Previously Untreated B-Cell Chronic Lymphocytic Leukemia (B-CLL) | March 2006 | |
| NCT00927797 | Unknown status | Phase 2 | Interventional Study on Pentostatin, Cyclophosphamide and Rituximab in Indolent B-Cell Non-Hodgkin-Lymphoma (B-NHL) | February 2005 | January 2012 |
| NCT00800943 | Unknown status | Phase 2 | Study of Subcutaneous Campath-1H in Patients With B-Cell CLL and Residual Disease After Chemotherapy | December 2003 | August 2010 |
| NCT03110640 | Unknown status | Phase 1 | Anti-CD19 CAR T Infusion Combined With Allogeneic Stem Cell Transplantation for B-cell Leukemia/Lymphoma | October 1, 2016 | September 2021 |
| NCT01864889 | Unknown status | N/A | Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by CART19 | April 2013 | April 2017 |
| NCT02685670 | Unknown status | Phase 1/Phase 2 | Competitive Transfer of αCD19-TCRz-CD28 and αCD19-TCRz-CD137 CAR-T Cells for B-cell Leukemia/Lymphoma | February 2016 | December 2019 |
| NCT03757000 | Unknown status | Phase 1 | A Phase I Study of YY-20394 in Patients With B Cell Hematologic Malignancies | December 25, 2017 | May 30, 2019 |
| NCT01735604 | Unknown status | Phase 1/Phase 2 | Genetically Engineered Lymphocyte Therapy in Treating Patients With Lymphoma That is Resistant or Refractory to Chemotherapy | January 2013 | October 2018 |
| NCT00336206 | Unknown status | N/A | Low Dose Alemtuzumab for Consolidation and Maintenance of Patients With B-Cell Chronic Lymphocytic Leukemia | July 2006 | October 2009 |
| NCT02315118 | Unknown status | Phase 1/Phase 2 | Pilot Study of Autologous T Lymphocytes With ADCC in Patients With CD20-Positive B-Cell Malignancies | December 2014 | December 2018 |
| NCT00845104 | Withdrawn | Phase 2 | Fludarabine Phosphate, Rituximab, and Bevacizumab in Treating Patients With B-Cell Chronic Lymphocytic Leukemia That Has Relapsed or Not Responded To Treatment | January 2009 | |
| NCT02298816 | Withdrawn | B-Cell Hematologic Malignancy Vaccination Registry | August 2014 | December 2025 | |
| NCT00485966 | Withdrawn | Phase 2 | Study Evaluating Effects of CX-3543 in Patients With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia | June 2007 | June 2008 |
| NCT00918450 | Withdrawn | Phase 2 | Study Assessing the Safety and Efficacy of ABT-263 in Subjects With B-cell Chronic Lymphocytic Leukemia (CLL) Who Have Failed at Least One Prior Fludarabine-containing Regimen | March 2010 |
- OrphaNumber from OrphaNet (Orphanet)
- 67038